MiMedx Group, Inc. MDXG, an integrated developer, manufacturer and marketer of patent protected
regenerative biomaterials and bioimplants processed from human amniotic
membrane, announced today that the Company has a meeting scheduled with the
Food and Drug Administration ("FDA") to discuss the recent Untitled Letter it
received from that agency.
The FDA has scheduled the meeting for October 16, 2013. Parker H. Petit,
Chairman and CEO, said, "In the meantime, we will continue to communicate with
the FDA in preparation for the scheduled meeting. MiMedx has already responded
in writing to the FDA regarding the Untitled Letter. In our correspondence, we
provided clear support for our position that our micronized products are
minimally manipulated, and we reiterated our desire to work with the agency to
resolve this issue as quickly as possible."
As the Company gains clarification through interaction with the FDA, MiMedx
will communicate updated information to its shareholders.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in